
Please try another search
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Name | Age | Since | Title |
---|---|---|---|
Jeffrey Allen Bailey | 63 | 2023 | Independent Director |
Kevin C. Tang | 58 | 2024 | Independent Chairman |
Craig A. Johnson | 63 | 2024 | Independent Director |
Peter S. Greenleaf | 55 | 2019 | President, CEO & Director |
Tina S. Nova | 71 | 2025 | Independent Director |
Kathy L. Goetz | 58 | 2025 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review